GKB Ophthalmics P/E Ratio
Current P/E Ratio
10.56
Low Valuation
Low - May indicate good value opportunity
GKB Ophthalmics (GKB) P/E ratio is 10.56 (Low), EPS (TTM) ₹2.42, current price ₹64.05 on BSE — Low - May indicate good value opportunity. Analyse GKB Ophthalmics ownership structure to track promoter, FII and institutional holdings.
Current Valuation Metrics
P/E Ratio
10.56
Current Price
₹64.05
EPS (TTM)
₹2.42
Exchange
BSE
Valuation Signal
Signal
Undervalued
Sector Context
Sector Average
55.06
Sector Median
30.69
Sector Rank
#11 of 194
Sector Percentile
5.7%
Earnings Breakdown (TTM)
TTM EPS
₹-5.50
Mar 2026
₹0.38
Sept 2025
₹3.17
GKB P/E Ratio — Valuation Signal & Historical Context
GKB Ophthalmics P/E 10.56 — signal: Undervalued. For live price, revenue and the complete fundamental profile, see GKB stock price BSE.
- Stock appears undervalued with PE of 10.56, suggesting potential buying opportunity
- Trading at discount to sector average PE of 55.06
GKB vs Healthcare Peers — P/E Ratio Comparison
GKB Ophthalmics P/E 10.56 vs Healthcare average 55.06, median 30.69 — range 2.86–879.0.
Sector Average
55.06
Sector Median
30.69
Lowest P/E
2.86
Highest P/E
879.0
Companies
194
| Company | Symbol | P/E Ratio | Market Cap (₹ Cr) | Valuation |
|---|---|---|---|---|
| Murae Organisor | MURAE | 2.86 | ₹41 | Low |
| Sunrest Lifescience | SUNREST | 3.5 | ₹30 | Low |
| Phaarmasia | PHRMASI | 4.06 | ₹68 | Low |
| Sun Pharma Advanced Rese… | SPARC | 4.97 | ₹7,724 | Low |
| Shelter Pharma | SHELTER | 5.34 | ₹49 | Low |
| Mono Pharmacare | MONOPHARMA | 6.25 | ₹20 | Low |
| Zenith Drugs | ZENITHDRUG | 7.69 | ₹77 | Low |
| Amwill Health Care | AMWILL | 7.81 | ₹89 | Low |
| Brooks Laboratories | BROOKS | 8.06 | ₹206 | Low |
| Royal Sense | ROYAL | 8.24 | ₹59 | Low |